Skip to Content
Merck
CN
  • Molecular characterization and antibiotic resistance of clinical isolates of methicillin-resistant Staphylococcus aureus obtained from Southeast of Iran (Kerman).

Molecular characterization and antibiotic resistance of clinical isolates of methicillin-resistant Staphylococcus aureus obtained from Southeast of Iran (Kerman).

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica (2013-09-17)
Javid Sadeghi, Shahla Mansouri
ABSTRACT

Staphylococcus aureus infections, particularly infections caused by methicillin-resistant S. aureus (MRSA) strains, are emerging as a major public health problem. The aim of this study was to determine the prevalence of MRSA, antibiotic resistance profile and staphylococcal cassette chromosome mec (SCCmec) type of MRSA isolates obtained from clinical samples. Totally, 162 S. aureus isolates were obtained from clinical samples at three university hospitals in Kerman, Iran from March 2011 to February 2012. All isolates were identified as S. aureus by phenotypic methods and confirmed by PCR amplification of the nuc gene. MRSA isolates were screened by phenotypic tests and confirmed by presence of mecA gene. The minimum inhibitory concentrations (MICs) of the MRSA isolates against antibacterial agents were determined by E-test. All isolates were analyzed by PCR for the presence of mecA and pvl genes. SCCmec typing of MRSA isolates was performed by multiplex PCR assay. Strain typing was carried out with REP-PCR. Using mecA gene PCR and phenotypic methods, 56.8% of the isolates were identified as MRSA. All MRSA isolates were susceptible to vancomycin and linezolid. The sensitivity of MRSA isolates to trimethoprim-sulfamethoxazole, clindamycin, ciprofloxacin, gentamicin, and erythromycin was 70.66, 66.53, 42.4, 38.05, and 29.35%, respectively. The most frequent SCCmec types were type III (48.31%) followed by type V (19.1%), type I (16.85%), and type IV (3.37%). The pvl gene was detected in 3.08% of isolates (two MRSA and three MSSA isolates). REP-PCR typing divided the 92 MRSA isolates into 10 distinct clusters. Our results indicate that vancomycin and linezolid are the most effective antibacterial agents against MRSA isolates and SCCmec type III is predominant in MRSA strains in this area.

MATERIALS
Product Number
Brand
Product Description

Supelco
Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Ciprofloxacin HCl, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Erythromycin, tested according to Ph. Eur.
Sigma-Aldrich
Erythromycin standard solution, 1 mg/mL in H2O
Sigma-Aldrich
Erythromycin, BioReagent, suitable for cell culture
Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Sigma-Aldrich
Erythromycin, meets USP testing specifications
USP
Erythromycin, United States Pharmacopeia (USP) Reference Standard
Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard
Supelco
Ciprofloxacin, VETRANAL®, analytical standard
Supelco
Ciprofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Clindamycin hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Vancomycin hydrochloride from Streptomyces orientalis, ≥900 μg per mg (as vancomycin base)
Sigma-Aldrich
Clindamycin hydrochloride, lincosamide antibiotic
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
USP
Clindamycin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Cotrimoxazole, Ready Made Solution, 100 mg/mL in DMSO
USP
Ciprofloxacin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Clindamycin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Ciprofloxacin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Ciprofloxacin, European Pharmacopoeia (EP) Reference Standard
Ciprofloxacin hydrochloride for peak identification, European Pharmacopoeia (EP) Reference Standard